F etal nuchal cystic hygroma (CH) is a very rare disease. The incidence of CH is between 1/1000 and 1/6000, and it is a rare malformation that occurs in the vascular and lymphatic systems. [1] CH was first defined by Redenbacher in 1828. [2] In CH, the etiology is not clearly understood, but it is known to be not neoplastic. [3] CH is frequently seen in the nape region. [4] However, 5% cases with CH may occur in the axillary, mediastinum, abdomen, and retroperitone-al mesenteric regions. [5] CH usually begins to develop after the sixth week of gestation. It is likely to be diagnosed in the routine ultrasound (USG) examination during the first trimester of pregnancy. [6] However, the ultrasonographic diagnosis of CH is usually made at the end of the first trimester and at the beginning of the second trimester. [7, 8] It is known that fetal outcomes are poor in the presence of CH. [9] However, when the long-term prognosis of live